Research and Markets has announced the addition of the Decision Resources report "Protein-Protein Interactions: Are They Now Druggable Targets?" to their offering.
This Decision Resources report discusses why protein-protein interactions are so hard to target, describe general strategies for targeting them, and present case studies of protein-protein interaction drug discovery.
It also describes projects of three major companies involved in this area and discusses the outlook for this field.
Researchers have been developing a body of science and technology to enable them to exploit protein-protein interactions as drug targets.
The toolkit of technologies aimed at addressing the major challenges in drug discovery for protein-protein interactions encompasses structure-based drug design, peptide-based technologies, combinatorial and medicinal chemistry, fragment-based screening, and whole-pathway cellular assays.
Recently, corporate and academic researchers have discovered several compounds that modulate protein-protein interactions.
The most advanced compounds in this field are thrombopoietin mimetics that arose from a collaboration between Ligand and GSK: eltrombopag (SB-497115) and SB-559448 are in Phase II and Phase I clinical trials, respectively.
Preclinical compounds targeting protein-protein interactions in development focus mainly on cancer.
Although research to discover small-molecule drugs that target protein-protein interactions is still at an early stage, accelerated activity in this area is expected as compounds move through clinical trials and as the science and technology base continues to develop.